跳到正文
原文
MedPage Today·· 4 天前精选AI 评分73

Tirzepatide在青少年肥胖治疗中的III期临床试验结果显示显著降低BMI

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

AI 导读

Tirzepatide在青少年肥胖治疗中的III期临床试验显示,72周后一次每周注射一次的Tirzepatide联合健康生活方式干预,使患者平均BMI降低18.5%,显著优于安慰剂组。研究还显示Tirzepatide在改善代谢指标方面也表现出色,但需注意其胃肠道副作用。

推荐理由

研究显示Tirzepatide在青少年肥胖治疗中显著降低BMI,为该领域提供了重要数据。

正文 · 原文

— Over half of SURMOUNT-ADOLESCENTS patients no longer met clinical threshold for obesity

November 15, 2026 • 4 min read

NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed.

At week 72, once-weekly tirzepatide paired with a healthy lifestyle intervention led to an 18.5% mean BMI reduction compared with a 0.5% increase with placebo, meeting the primary endpoint for superiority (estimated treatment difference -19.0 percentage points, 95% CI -23.9 to -14.1, P<0.001).

All 10 key secondary outcomes also significantly favored tirzepatide, including reductions in waist circumference and body weight and improvements in physical functioning, reported Aaron S. Kelly, PhD, of the University of Minnesota Medical School in Minneapolis, and colleagues.

The findings were presented at the ObesityWeek annual meeting and simultaneously published in JAMA.

"Tirzepatide-treated participants had greater reductions in body weight compared with placebo, and 48.1% achieved at least 20% reduction in BMI, accompanied by improvements in measures of obesity severity, cardiometabolic risk factors, and physical functioning," the authors wrote.

Over half (53.5%) of those on tirzepatide no longer met the clinical threshold for obesity (BMI below the 95th percentile) at week 72 compared with 7.1% on placebo.

The dual GLP-1/GIP receptor agonist was approved in November 2023 for adults with obesity. It also holds indications for type 2 diabetes (Mounjaro; for ages 10 years and older) and for adults with obesity-related moderate-to-severe obstructive sleep apnea.

Rival GLP-1 agent semaglutide (Wegovy) was approved for adolescent obesity in December 2022.

The magnitude of weight loss aligns with results from the adult SURMOUNT-1 trial -- which showed roughly 20% body weight reduction with the 10-mg and 15-mg doses -- and extends prior pediatric findings from SURPASS-PEDS, in which tirzepatide improved glycemic control and lowered BMI in youth with type 2 diabetes (T2D).

In an accompanying editorial, William Heerman, MD, MPH, of Vanderbilt Health in Nashville, and colleagues noted that "for many years, nonsurgical treatment options for pediatric obesity were limited to behavioral interventions or pharmacotherapy, with modest effectiveness."

The treatment landscape shifted in 2023 when the American Academy of Pediatrics advised offering pharmacotherapy alongside behavioral intervention for adolescents ages 12 and older with obesity.

"SURMOUNT-ADOLESCENTS expands what is possible in the treatment of adolescent obesity," Heerman's group wrote. "But the success of this trial and others like it also raises the bar for the field."

"Having established that substantial reductions in obesity severity are achievable, the next generation of research must determine how to personalize medication choice, whether these treatments produce durable improvements in obesity-related disease, and how they can be delivered safely, sustainably, and effectively in clinical practice," they continued.

Heerman and colleagues cautioned against translating the trial's dosing protocol directly into routine care. While the trial escalated participants based primarily on tolerability, resulting in 61.6% of completers reaching the 15-mg dose at week 72, they emphasized that medications producing bariatric surgery-level weight loss should not involve "reflexive escalation to the maximum tolerated dose." Instead, clinicians should individualize titration based on treatment response, rate of weight loss, nutritional adequacy, physical function, eating behaviors, and adverse effects.

The double-blind trial was conducted at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the U.S. from October 2023 to June 2026. It enrolled 160 adolescents, ages 12 to <18 years, with obesity (BMI ≥95th percentile) or overweight (BMI ≥85th to <95th percentile) plus at least one weight-related complication.

Following a 12-week healthy lifestyle lead-in, participants were randomized 2:1 to once-weekly subcutaneous tirzepatide (escalated to a maximum tolerated dose of 5, 10, or 15 mg; n=109) or placebo (n=51) for 72 weeks alongside ongoing diet and physical activity counseling.

At baseline, average age was 14.6 years, 61.9% were female, mean weight was 242 lb, and mean BMI was 38.6. One patient each in the placebo group had T2D and one patient in the tirzepatide group had overweight with prediabetes. Most had severe class 2 or class 3 obesity.

At week 72, 79.6% of tirzepatide-treated participants achieved a BMI reduction of at least 5% versus 28.5% on placebo (risk difference 51.2 percentage points, 95% CI 36.3-66.1, P<0.001). BMI reductions of at least 10%, 15%, and 20% were achieved by 71.4%, 63.4%, and 48.1% of the tirzepatide group, respectively, versus 19.5%, 12.4%, and 7.9% of the placebo group.

Tirzepatide also significantly improved systolic and diastolic blood pressure, triglycerides, glycemic measures (fasting glucose, HbA1c, and fasting insulin), and lipid profiles, lowering total, LDL, VLDL, and non-HDL cholesterol while raising HDL cholesterol.

As expected, gastrointestinal events were the most common adverse events (AE; 81.5% on tirzepatide vs 54.9% on placebo), though most were mild to moderate and concentrated during dose escalation. Antiemetics were used by 22.2% on tirzepatide and 3.9% on placebo, while antidiarrheals were used by 8.3% and 5.9%, respectively.

Among the 108 participants who received at least one tirzepatide dose, 10 (9.3%) discontinued due to AEs versus none on placebo.

"Despite substantial BMI reduction, height standard deviation score remained stable, and pubertal (Tanner stage) progression was similar between the treatment groups over 72 weeks and consistent with expected growth and maturation for adolescents, suggesting no apparent disruption of expected growth or maturation during the trial," Kelly's group noted.

Because only one participant had overweight, the findings "should therefore be understood primarily as evidence for treating adolescents with obesity, particularly those with more severe obesity, rather than as evidence supporting pharmacological treatment of overweight," Heerman and colleagues wrote.

The researchers also acknowledged a lack of racial and ethnic diversity (83.4% white and 96.9% non-Hispanic), potentially limiting generalizability.

来源:MedPage Today · medpagetoday.com